Vitamin D and Grass Pollen Specific Immunotherapy

• Status: Completed
• Trial end date: 2015-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Allergen-specific immunotherapy is the only causal therapy of Immunoglobulin E-induced allergies like allergic rhinoconjunctivitis. Despite progress during the last decades it is limited by a long treatment time and high non-responder frequency. Based on experimental and epidemiological evidences we hypothesize that vitamin D can act as an effective immunomodulatory adjuvant to overcome these limitations.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Charite University, Berlin, Germany
• Treatments: Cholecalciferol; Ergocalciferols; Vitamin D; Vitamins

Criteria

Inclusion Criteria:

• written informed consent

• relative Vitamin D deficiency

• clinical relevant grass pollen allergy

• positive intradermal test with grass pollen

• forced expiratory volume at one second (FEV1) > 70%

Exclusion Criteria:

• current specific immunotherapy

• instable allergic asthma

• pregnancy and lactation

• treatment with immunomodulators or immunosuppressive drugs

• sarcoidosis, chronic diseases, malignancy